Latest & greatest articles for methylprednisolone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on methylprednisolone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on methylprednisolone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for methylprednisolone

41. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis.

Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. 15269315 2004 07 22 2004 08 02 2013 11 21 1533-4406 351 4 2004 Jul 22 The New England journal of medicine N. Engl. J. Med. Methylprednisolone, valacyclovir, or the combination for vestibular neuritis. 354-61 Vestibular neuritis is the second most common cause of peripheral vestibular vertigo. Its assumed cause is a reactivation of herpes simplex virus type 1 infection. Therefore, corticosteroids, antiviral agents (...) , or a combination of the two might improve the outcome in patients with vestibular neuritis. We performed a prospective, randomized, double-blind, two-by-two factorial trial in which patients with acute vestibular neuritis were randomly assigned to treatment with placebo, methylprednisolone, valacyclovir, or methylprednisolone plus valacyclovir. Vestibular function was determined by caloric irrigation, with the use of the vestibular paresis formula (to measure the extent of unilateral caloric paresis) within 3

NEJM2004

42. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial.

Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. 11809183 2002 01 25 2002 02 13 2015 06 16 0140-6736 359 9300 2002 Jan 05 Lancet (London, England) Lancet Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. 23 (...) -9 Treatment of adults with autoimmune thrombocytopenic purpura (AITP) is based more on individual experience than on results of controlled studies. We compared intravenous immunoglobulin with high-dose methylprednisolone in untreated adults with severe AITP and assessed efficacy of subsequent oral steroids compared with placebo. Primary outcome was number of days with platelet count greater than 50 x 10(9)/L within the first 21 days. We did a randomised multicentre trial based on a 232 design

Lancet2002

43. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Combination therapy with pulse cy... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2001 ) Volume: 135 , Issue: 4 , Pages: 248-257 PubMed: Available from or Find this paper at: Abstract BACKGROUND: Controlled trials (...) in lupus nephritis have demonstrated that cyclophosphamide therapy is superior to corticosteroid therapy alone. The long-term effectiveness and side-effect profiles of pulse immunosuppressive regimens warrant further study. OBJECTIVE: To define the long-term risk and benefit of monthly treatment with boluses of methylprednisolone, cyclophosphamide, or both. DESIGN: Extended follow-up (median, 11 years) of a randomized, controlled trial. SETTING: U.S. government research hospital. PATIENTS: 82 patients

Annals of Internal Medicine2001

44. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations

A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations Miller D M, Weinstock-Guttman B, Bethoux F, Lee J C, Beck G, Block V, Durelli L, LaMantia L, Barnes D, Sellebjerg F, Rudick R A Authors' objectives To assess methylprednisolone (MP) at different doses, and in comparison with other (...) steroid products, in the treatment of multiple sclerosis exacerbations. Searching MEDLINE was searched from 1981 to 1998, and EMBASE from 1980 to 1998, combining 'Multiple Sclerosis' (as an index term) with 'Methylprednisolone' (either as an index term or in 'authors, title or abstract'). The references of identified articles and recent review articles were also examined. No restrictions on publication language were specified. Study selection Study designs of evaluations included in the review

DARE.2000

45. High dose methylprednisolone in the management of acute spinal cord injury: a systematic review from a clinical perspective

High dose methylprednisolone in the management of acute spinal cord injury: a systematic review from a clinical perspective High dose methylprednisolone in the management of acute spinal cord injury: a systematic review from a clinical perspective High dose methylprednisolone in the management of acute spinal cord injury: a systematic review from a clinical perspective Short D J, El Masry W S, Jones P W Authors' objectives To evaluate the evidence for an effect of high-dose methylprednisolone (...) (MPSS) on neurological improvement, following acute spinal cord injury (ASCI). Searching MEDLINE was searched from 1966 through December 1999 using the terms 'spinal cord injury' and 'methylprednisolone', or 'spinal cord injury' and 'dexamethasone', with no other restrictions. Additional relevant studies were located by examining the references of a review for pharmacological treatment of ASCI on the Cochrane Database of Systematic Reviews, and by manually checking the reference lists

DARE.2000

46. Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review

Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review Sauerland S, Nagelschmidt M, Mallmann P, Neugebauer E A Authors' objectives To conduct a risk-benefit analysis using a meta-analysis, for the comparison of complication rates (...) and clinical advantages associated with the use of high-dose methylprednisolone in surgical patients. Searching PubMed and the Cochrane Library (Issue 2, 2000) were searched using the term 'methylprednisolone' and the publication type 'randomised controlled trial'. Both searches were repeated in August 2000. The references of all articles and two related Cochrane reviews were checked for further studies. The manufacturer of a commonly-used MPSS was also contacted for further information. Study selection

DARE.2000

47. Intrathecal methylprednisolone for intractable postherpetic neuralgia.

Intrathecal methylprednisolone for intractable postherpetic neuralgia. 11087880 2000 11 08 2000 11 30 2013 11 21 0028-4793 343 21 2000 Nov 23 The New England journal of medicine N. Engl. J. Med. Intrathecal methylprednisolone for intractable postherpetic neuralgia. 1514-9 There is no effective treatment for intractable postherpetic neuralgia. Because there is evidence that postherpetic neuralgia has an inflammatory component, we assessed treatment with intrathecally administered (...) methylprednisolone to reduce pain in patients with this disorder. We enrolled 277 patients who had had intractable postherpetic neuralgia for at least one year, 270 of whom were followed for two years. The patients were randomly assigned to receive intrathecal methylprednisolone and lidocaine (3 ml of 3 percent lidocaine with 60 mg of methylprednisolone acetate, 89 patients), lidocaine alone (3 ml of 3 percent lidocaine, 91 patients), or no treatment (90 patients) once per week for up to four weeks. Each weekly

NEJM2000

48. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus.

Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. BACKGROUND: Neuropsychiatric involvement in systemic lupus erythematosus is complex and several clinical presentations are related to this disease such as: convulsions, chronic headache, transverse myelitis, vascular brain disease, psychosis and neural cognitive dysfunction. OBJECTIVES: To assess the efficacy and safety of cyclophosphamide and methylprednisolone (...) cyclophosphamide to methylprednisolone were to be included. Patients of any age and gender were included if they fulfilled the criterion of the American Rheumatology Association for the diagnosis of systemic lupus erythematosus and presented with any one of the following neuropsychiatric events; convulsions, organic brain syndrome; cranial neuropathy. Outcome measures included the following: a) Overall mortality (primary event); b) Motor and psychiatric deficit (primary event); c) Clinical improvement

Cochrane2000

49. Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial.

Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial. 10506042 1999 11 05 1999 11 05 2014 06 15 0959-8138 319 7214 1999 Oct 02 BMJ (Clinical research ed.) BMJ Injection with methylprednisolone proximal to the carpal tunnel: randomised double blind trial. 884-6 To assess the effect of a 40 mg methylprednisolone injection proximal to the carpal tunnel in patients with the carpal tunnel syndrome. Randomised double blind placebo controlled trial. Outpatient (...) neurology clinic in a district general hospital. Patients with symptoms of the carpal tunnel syndrome for more than 3 months, confirmed by electrophysiological tests and aged over 18 years. Injection with 10 mg lignocaine (lidocaine) or 10 mg lignocaine and 40 mg methylprednisolone. Non-responders who had received lignocaine received 40 mg methylprednisolone and 10 mg lignocaine and were followed in an open study. Participants were scored as having improved or not improved. Improved was defined

BMJ1999 Full Text: Link to full Text with Trip Pro

50. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial

Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club1998

51. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial.

Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. 9669790 1998 07 22 1998 07 22 2016 10 17 0098-7484 280 2 1998 Jul 08 JAMA JAMA Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. 159-65 No pharmacological therapeutic protocol has been found effective in modifying the clinical course of acute respiratory distress syndrome (ARDS) and (...) mortality remains greater than 50%. To determine the effects of prolonged methylprednisolone therapy on lung function and mortality in patients with unresolving ARDS. Randomized, double-blind, placebo-controlled trial. Medical intensive care units of 4 medical centers. Twenty-four patients with severe ARDS who had failed to improve lung injury score (LIS) by the seventh day of respiratory failure. Sixteen patients received methylprednisolone and 8 received placebo. Methylprednisolone dose was initially

JAMA1998

52. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. 9093250 1997 04 25 1997 04 25 2015 06 16 0140-6736 349 9056 1997 Mar 29 Lancet (London, England) Lancet Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. 902-6 An intravenous rather than oral course of methylprednisolone is often prescribed for treating acute relapses in multiple sclerosis (MS) despite the lack of evidence to support this route (...) of administration. Our double-blind placebo-controlled randomised trial was designed to compare the efficacy of commonly used intravenous and oral steroid regimens in promoting recovery from acute relapses in MS. 42 patients with clinically definite relapse in MS received oral, and 38 intravenous, methylprednisolone. Clinical measurements at entry and at 1 week, 4 weeks, 12 weeks, and 24 weeks included Kurtzke's expanded disability status scale (EDSS), Hauser's Ambulatory Index, and an arm-function index

Lancet1997

53. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury

Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury 9168289 1997 06 09 1997 06 09 2016 11 24 0098-7484 277 20 1997 May 28 JAMA JAMA Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third (...) National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. 1597-604 To compare the efficacy of methylprednisolone administered for 24 hours with methyprednisolone administered for 48 hours or tirilazad mesylate administered for 48 hours in patients with acute spinal cord injury. Double-blind, randomized clinical trial. Sixteen acute spinal cord injury centers in North America. A total of 499 patients with acute spinal cord injury diagnosed in National Acute

JAMA1997

54. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease.

High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. 8107739 1994 03 24 1994 03 24 2013 11 21 0028-4793 330 11 1994 Mar 17 The New England journal of medicine N. Engl. J. Med. High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. 733-7 The management of episodes of severe pain in patients with sickle cell disease is a difficult clinical problem. We studied 36 children (...) and adolescents with sickle cell disease who had 56 acute episodes of severe pain (44 in 27 patients with sickle cell anemia, 8 in 7 patients with sickle cell-hemoglobin C disease, and 4 in 2 patients with sickle cell-beta (+)-thalassemia). The patients were randomly assigned in double-blind fashion to receive an intravenous infusion of either saline placebo or high-dose methylprednisolone (15 mg per kilogram of body weight, to a maximum of 1000 mg) on their admission to the hospital and again 24 hours later

NEJM1994

55. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group.

Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group. 8094828 1993 03 25 1993 03 25 2015 06 16 0140-6736 341 8845 1993 Mar 06 Lancet (London, England) Lancet Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group. 586-90 Steroids have been beneficial in the treatment of demyelinating diseases with features similar to those of Guillain-Barré syndrome (...) (GBS). However, steroid treatment of GBS has been disappointing; in an earlier trial oral prednisolone was ineffective, although the dose was low and the sample small. We assessed the benefit of a high-dose steroid regimen in a large sample of patients with GBS in a multicentre, randomised, double-blind trial. 242 adult patients were randomised to receive intravenous methylprednisolone (IVMP) 500 mg (124 patients) or a placebo (118) daily for 5 days. Patients were diagnosed by standard clinical

Lancet1993

56. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group.

Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous Nephropathy Treatment Study Group. 1640953 1992 09 02 1992 09 02 2013 11 21 0028-4793 327 9 1992 Aug 27 The New England journal of medicine N. Engl. J. Med. Methylprednisolone plus chlorambucil as compared with methylprednisolone alone for the treatment of idiopathic membranous nephropathy. The Italian Idiopathic Membranous (...) Nephropathy Treatment Study Group. 599-603 Treatment with methylprednisolone and chlorambucil may protect renal function and increase the chance of remission of the nephrotic syndrome in patients with idiopathic membranous nephropathy. To determine whether similar results might be obtained with methylprednisolone alone, we compared the effects of methylprednisolone and chlorambucil with those of methylprednisolone alone in 92 patients with the nephrotic syndrome caused by idiopathic membranous nephropathy

NEJM1992

57. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. 1356175 1992 10 22 1992 10 22 2015 06 16 0140-6736 340 8822 1992 Sep 26 Lancet (London, England) Lancet Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. 741-5 Pulse cyclophosphamide is more effective than prednisone alone in preventing renal failure in lupus nephritis. We undertook a randomised, controlled (...) trial to find out whether pulse methylprednisolone could equal pulse cyclophosphamide in preserving renal function in patients with lupus nephritis, and whether there was a difference between long and short courses of pulse cyclophosphamide in preventing exacerbations. 65 patients (60 female, 5 male; median [range] age 29 [10-48] years) with severe lupus nephritis were assigned randomly to monthly pulse methylprednisolone for 6 months (25 patients), monthly pulse cyclophosphamide for 6 months (20

Lancet1992

58. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.

Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. 2017225 1991 05 20 1991 05 20 2013 11 21 0028-4793 324 19 1991 May 09 The New England journal of medicine N. Engl. J. Med. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. 1297-304 Immunosuppression is the most effective treatment for patients (...) with aplastic anemia, except for bone marrow transplantation. The best results are achieved with antilymphocyte globulin or cyclosporine. Patients have been treated successfully with a combination of both agents, but there has been no controlled evaluation of its efficacy. We conducted a randomized, multicenter trial in 84 patients not eligible for bone marrow transplantation, comparing treatment with antilymphocyte globulin and methylprednisolone (41 patients--the control group) with antilymphocyte

NEJM1991

59. Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis.

Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. 2202458 1990 10 04 1990 10 04 2013 11 21 0959-8138 301 6746 1990 Aug 04 BMJ (Clinical research ed.) BMJ Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis. 268-70 To assess whether monthly treatment with intravenous methylprednisolone enhances or accelerates (...) the effect of disease modifying drugs in patients with rheumatoid arthritis. A 12 month double blind, placebo controlled, multicentre trial in which patients with active rheumatoid arthritis were randomly allocated to receive pulses of either methylprednisolone or saline every four weeks for six months. At the start of the pulse treatment all patients were started on penicillamine or azathioprine. Four rheumatology departments in Denmark. 97 Patients (71 women, 26 men) aged 23-84 (mean 60) who had active

BMJ1990 Full Text: Link to full Text with Trip Pro

60. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.

A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. 2278545 1990 05 25 1990 05 25 2013 11 21 0028-4793 322 20 1990 May 17 The New England journal of medicine N. Engl. J. Med. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. 1405-11 Studies in animals (...) indicate that methylprednisolone and naloxone are both potentially beneficial in acute spinal-cord injury, but whether any treatment is clinically effective remains uncertain. We evaluated the efficacy and safety of methylprednisolone and naloxone in a multicenter randomized, double-blind, placebo-controlled trial in patients with acute spinal-cord injury, 95 percent of whom were treated within 14 hours of injury. Methylprednisolone was given to 162 patients as a bolus of 30 mg per kilogram of body

NEJM1990